"A multi-centre randomized, open-label phase II trial of erlotinib plus" by Michael Michael, Michael Johnston et al.

Skip to main content

Faculty of Science - Papers

Title

A multi-centre randomized, open-label phase II trial of erlotinib plus gemcitabine or gemcitabine monotherapy as first-line therapy in ECOG PS2 patients with chemo-naive advanced NSCLC

Authors

Michael Michael, Peter MacCallum Cancer Centre
Michael Johnston, Roche Prod Pty Ltd
Stephen Clarke
Richard De Boer, Royal Melbourne Hospital
Phillip R. Clingan, University of Wollongong
Nick Pavlakis, Royal N Shore Hosp

Document Type

Journal Article

Tell a Colleague
Print
Download Adobe Reader
COinS